Management and Treatment for Antiphospholipid Syndrome

Risk Stratification

Patients with antiphospholipid syndrome should be stratified based on antibody profile and clinical manifestations, with high-risk profiles including presence of lupus anticoagulant, double or triple antibody positivity, or persistently high antibody titers 1
Triple positivity indicates the highest risk for thrombotic events 1, 2

The American College of Chest Physicians recommends long-term anticoagulation with vitamin K antagonists (warfarin) with a target INR of 2.0-3.0 for patients with venous thromboembolism 3, 1, 2
Moderate-intensity warfarin (INR 2.0-3.0) provides optimal balance between thrombosis prevention and bleeding risk 2
High-intensity warfarin (INR 3.0-4.5) should be avoided as it does not provide additional benefit over moderate intensity but increases bleeding risk 3, 2

For patients meeting criteria for obstetric APS, combined therapy with low-dose aspirin and prophylactic-dose heparin is strongly recommended 1
In pregnant women with thrombotic APS, low-dose aspirin and therapeutic-dose heparin should be used throughout pregnancy and postpartum 1

For asymptomatic antiphospholipid antibody-positive patients, low-dose aspirin is recommended for primary prevention, especially in those with high-risk antibody profiles 1

In patients with positive anti-phospholipid antibodies who do not fulfill criteria for anti-phospholipid syndrome, antiplatelet therapy is recommended 4
Regular monitoring of anticoagulation therapy is essential, with more intensive monitoring for high-risk patients (triple-positive or double-positive with lupus anticoagulant) 1, 2

Avoid abrupt discontinuation of anticoagulation therapy as this significantly increases thrombosis risk 3
Ensure that diagnosis is based on persistent antibody positivity to avoid misdiagnosis 1
Testing for antiphospholipid antibodies should be deferred or repeated at least 4-6 weeks after acute thrombosis as protein levels may be altered during the acute phase 2

Patients with negative RF and CCP, high complements, and positive anti-PS/PT antibodies have a seronegative APS profile, which may still pose a thrombotic risk 5
The presence of anti-PS/PT antibodies is mainly associated with lupus anticoagulant presence and has shown favorable results regarding diagnostic value in APS patients 6

The American College of Chest Physicians recommends initiating low-dose aspirin 75-100 mg daily for primary prevention in patients with persistently positive moderate-to-high titers of antiphospholipid antibodies, even when they don't meet full APS criteria 5, 7
Data from cohort studies support the potential benefit from antiplatelet agents in primary prevention of cardiovascular disease and thrombotic events in patients with persistently positive antiphospholipid antibodies 5, 7

Aggressively managing hypertension, hyperlipidemia, and diabetes is crucial as these significantly amplify thrombotic risk in antiphospholipid antibody-positive patients 5
Repeat anti-PS/PT testing in 12 weeks is necessary to confirm persistent positivity, as transient antibodies do not warrant long-term anticoagulation 6
Do not routinely monitor with repeat antibody testing once persistence is confirmed, unless clinical status changes 6

The American College of Chest Physicians recommends moderate-intensity warfarin (INR 2.0-3.0) rather than higher intensity (INR 3.0-4.5) for antiphospholipid syndrome 8
Initiate warfarin with target INR 2.0-3.0 for long-term anticoagulation in patients with venous thromboembolism 9, 8
Warfarin with target INR 2.0-3.0 is reasonable for secondary prevention of arterial events including stroke/TIA in antiphospholipid antibody syndrome 9, 5, 7
Avoid direct oral anticoagulants (DOACs) including rivaroxaban and apixaban, as they are associated with increased thrombotic events compared to warfarin in APS patients 9